Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1–positive locally advanced/metastatic NSCLC

T.S.K Mok; Y.-L Wu; I Kudaba; D.M Kowalski; B.C Cho; H.Z Turna; G de Castro; V Srimuninnimit; K.K Laktionov; I Bondarenko; K Kubota; C Caglevic; B Karaszewska; T Dang; L Yin; J Penrod; G Lopes

doi:10.1093/annonc/mdz063

Back

Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1–positive locally advanced/metastatic NSCLC

Journal article

Open access

Peer reviewed

Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1–positive locally advanced/metastatic NSCLC

T.S.K Mok, Y.-L Wu, I Kudaba, D.M Kowalski, B.C Cho, H.Z Turna, G de Castro, V Srimuninnimit, K.K Laktionov, I Bondarenko, …

Annals of oncology, Vol.30, pp.i38-i38

2019-04

DOI: https://doi.org/10.1093/annonc/mdz063

PMID: 32131153

Files and links (1)

url

https://doi.org/10.1093/annonc/mdz063View

Published (Version of record) Open

Metrics

71 Record Views

See more details

Details

Title: Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1–positive locally advanced/metastatic NSCLC
Creators: T.S.K Mok - Clinical Oncology, State Key Laboratory of South China, Chinese University of Hong Kong, Hong Kong, China
Y.-L Wu - Guandong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangdong, China
I Kudaba - Latvian Oncology Center, Riga East Clinical University, Riga, Latvia
D.M Kowalski - The Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland
B.C Cho - Yonsei Cancer Center, Seoul, Republic of Korea
H.Z Turna - Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey
G de Castro - Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil
V Srimuninnimit - Siriraj Hospital, Bangkok, Thailand
K.K Laktionov - N.N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation
I Bondarenko - Dnipropetrovsk Medical Academy, Dnipro, Ukraine
K Kubota - Nippon Medical School Hospital, Tokyo, Japan
C Caglevic - Medical Oncology Service, Department of Medical Oncology, Clinica Alemana Santiago, Medicine Faculty Clinica Alemana, Universidad del Desarrollo, Santiago, Chile
B Karaszewska - Przychodnia Lekarska KOMED, Konin, Poland
T Dang - Merck & Co., Inc., Kenilworth, NJ, USA
L Yin - Merck & Co., Inc., Kenilworth, NJ, USA
J Penrod - Merck & Co., Inc., Kenilworth, NJ, USA
G Lopes - Sylvester Comprehensive Cancer Center at the University of Miami, Miami, FL, USA
Publication Details: Annals of oncology, Vol.30, pp.i38-i38
Publisher: Elsevier Ltd
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
PMID: 32131153
Record Identifier: 991031597576502976